118 related articles for article (PubMed ID: 18757185)
1. BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Geffen Y; Nudelman A; Gil-Ad I; Rephaeli A; Huang M; Savitsky K; Klapper L; Winkler I; Meltzer HY; Weizman A
Eur Neuropsychopharmacol; 2009 Jan; 19(1):1-13. PubMed ID: 18757185
[TBL] [Abstract][Full Text] [Related]
2. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Nudelman A; Gil-Ad I; Shpaisman N; Terasenko I; Ron H; Savitsky K; Geffen Y; Weizman A; Rephaeli A
J Med Chem; 2008 May; 51(9):2858-62. PubMed ID: 18363346
[TBL] [Abstract][Full Text] [Related]
3. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
Fitzgerald PB
Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163
[TBL] [Abstract][Full Text] [Related]
4. An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine.
Anand R; Geffen Y; Vasile D; Dan I
Clin Neuropharmacol; 2010; 33(6):297-302. PubMed ID: 20921890
[TBL] [Abstract][Full Text] [Related]
5. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
7. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans.
Appel L; Geffen Y; Heurling K; Eriksson C; Antoni G; Kapur S
Eur Neuropsychopharmacol; 2009 Dec; 19(12):841-50. PubMed ID: 19717284
[TBL] [Abstract][Full Text] [Related]
8. Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex.
Huang M; Li Z; Ichikawa J; Dai J; Meltzer HY
Brain Res; 2006 Jul; 1099(1):44-55. PubMed ID: 16824491
[TBL] [Abstract][Full Text] [Related]
9. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
[TBL] [Abstract][Full Text] [Related]
10. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
[TBL] [Abstract][Full Text] [Related]
11. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
Amargós-Bosch M; Adell A; Artigas F
J Neurochem; 2007 Jul; 102(2):550-61. PubMed ID: 17394545
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
[TBL] [Abstract][Full Text] [Related]
14. [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol].
Kikumoto O; Okamoto Y; Hayakawa H; Yokota N; Kawai K; Motohashi N; Yamawaki S
Yakubutsu Seishin Kodo; 1993 Feb; 13(1):39-42. PubMed ID: 7686319
[TBL] [Abstract][Full Text] [Related]
15. Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat.
Lipska BK; Jaskiw GE; Braun AR; Weinberger DR
Biol Psychiatry; 1995 Aug; 38(4):255-62. PubMed ID: 8547448
[TBL] [Abstract][Full Text] [Related]
16. Changes in dopamine, serotonin and their metabolites in discrete brain areas of rat offspring after in utero exposure to cocaine or related drugs.
Henderson MG; McMillen BA
Teratology; 1993 Nov; 48(5):421-30. PubMed ID: 7508151
[TBL] [Abstract][Full Text] [Related]
17. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
[TBL] [Abstract][Full Text] [Related]
18. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
19. Specific abnormalities in serotonin release in the prefrontal cortex of isolation-reared rats measured during behavioural performance of a task assessing visuospatial attention and impulsivity.
Dalley JW; Theobald DE; Pereira EA; Li PM; Robbins TW
Psychopharmacology (Berl); 2002 Nov; 164(3):329-40. PubMed ID: 12424557
[TBL] [Abstract][Full Text] [Related]
20. Clozapine decreases exploratory activity and increases anxiety-like behaviour in the Wistar-Kyoto rat but not the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder.
Mc Fie S; Sterley TL; Howells FM; Russell VA
Brain Res; 2012 Jul; 1467():91-103. PubMed ID: 22658977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
